2026-2034年全球抗凝血酶市場規模、佔有率、趨勢和成長分析報告

預計抗凝血酶市場將從 2025 年的 9.3 億美元成長到 2034 年的 14.4 億美元，2026 年至 2034 年的複合年成長率為 4.94%。

由於血栓性疾病和血液凝固併發症的發生率不斷上升，全球抗凝血酶市場正穩步擴張。抗凝血酶在預防異常血栓形成方面發揮著至關重要的作用，尤其是在手術和高風險懷孕期間。人們對心血管健康的日益關注也促進了治療方法的應用。醫療基礎設施的擴建進一步推動了市場成長。

成長要素包括血漿衍生抗凝血酶和重組抗凝血酶療法的進步。遺傳性凝血障礙盛行率的上升推動了對標靶治療的需求。外科手術量和加加護病房入院人數的增加也是重要的推動因素。此外，診斷篩檢的改善提高了早期療育率。

隨著新型抗凝血療法的研發不斷推進，未來前景樂觀。更安全、更有效的製劑的研發將擴大病患的用藥範圍。新興市場對先進醫療服務的投資也帶來了新的成長機會。預計抗凝血酶市場將穩定持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球抗凝血酶市場：依技術與應用分類

• 市場分析、洞察與預測
• 治療
• 調查
• 診斷

第5章：全球抗凝血酶市場：依來源分類

• 市場分析、洞察與預測
• 人類
• 羊奶
• 其他

第6章：全球抗凝血酶市場：依劑型分類

• 市場分析、洞察與預測
• 冷凍乾燥製劑
• 液體

第7章 全球抗凝血酶市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 亞太其他地區
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Grifols SA
  • Octapharma AG
  • LFB USA
  • CSL
  • Takeda Pharmaceutical Company Limited
  • Lee BioSolutions
  • Scrippslabs
  • Kedrion
  • Koliber Biosciences
  • Exonbio
  • Helena Laboratories Corporation
  • MyBioSource.Com

The Antithrombin Market size is expected to reach USD 1.44 Billion in 2034 from USD 0.93 Billion (2025) growing at a CAGR of 4.94% during 2026-2034.

The Global Antithrombin market has expanded steadily due to increasing incidence of thrombotic disorders and blood clotting complications. Antithrombin plays a critical role in preventing abnormal clot formation, especially during surgeries and high-risk pregnancies. Rising awareness about cardiovascular health has contributed to growing treatment adoption. Expanding healthcare infrastructure further supports market development.

Growth drivers include advancements in plasma-derived and recombinant antithrombin therapies. Increased prevalence of genetic clotting disorders boosts demand for targeted treatments. Growing surgical procedures and intensive care admissions also contribute significantly. Additionally, improvements in diagnostic screening enhance early intervention rates.

Future prospects appear favorable as research into novel anticoagulant therapies progresses. Development of safer and more effective formulations will expand patient access. Emerging markets investing in advanced healthcare services present new growth opportunities. The antithrombin market is expected to witness stable and sustained expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology Application

• Therapeutics
• Research
• Diagnostics

By Source

• Human
• Goat Milk
• Others

By Dosage Form

• Lyophilized
• Liquid

COMPANIES PROFILED

• Grifols SA, Octapharma AG, LFB USA, CSL, Takeda Pharmaceutical Company Limited, Lee BioSolutions, scrippslabs, Kedrion, Koliber Biosciences, exonbio, Helena Laboratories Corporation, MyBioSourcecom
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTITHROMBIN MARKET: BY TECHNOLOGY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology Application
• 4.2. Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Research Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTITHROMBIN MARKET: BY SOURCE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Source
• 5.2. Human Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Goat Milk Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTITHROMBIN MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Dosage Form
• 6.2. Lyophilized Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Liquid Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTITHROMBIN MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Technology Application
  • 7.2.2 By Source
  • 7.2.3 By Dosage Form
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Technology Application
  • 7.3.2 By Source
  • 7.3.3 By Dosage Form
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Technology Application
  • 7.4.2 By Source
  • 7.4.3 By Dosage Form
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Technology Application
  • 7.5.2 By Source
  • 7.5.3 By Dosage Form
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Technology Application
  • 7.6.2 By Source
  • 7.6.3 By Dosage Form
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANTITHROMBIN INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Grifols S.A
  • 9.2.2 Octapharma AG
  • 9.2.3 LFB USA
  • 9.2.4 CSL
  • 9.2.5 Takeda Pharmaceutical Company Limited
  • 9.2.6 Lee BioSolutions
  • 9.2.7 Scrippslabs
  • 9.2.8 Kedrion
  • 9.2.9 Koliber Biosciences
  • 9.2.10 Exonbio
  • 9.2.11 Helena Laboratories Corporation
  • 9.2.12 MyBioSource.Com